Prelude Therapeutics (NASDAQ:PRLD) Receives “Buy” Rating from HC Wainwright
MarketBeatHC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Prelude Therapeutics in a research note on Monday.
HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Prelude Therapeutics in a research note on Monday.